Advertisement

Excess Free Light Chains in Serum Immunofixation Electrophoresis: Attributes of a Distinctive Pattern

  • Bharani Vani
  • Aggarwal Ritu
  • Sharma Praveen
  • Malhotra Pankaj
  • Ranjana Minz
Original Article
  • 26 Downloads

Abstract

Serum and urine protein electrophoresis and immunofixation are essential for identification and categorization of M protein/monoclonal protein. Based on the number of discrete bands identified the condition can be a monoclonal, biclonal or triclonal gammopathy. A subset of cases show an interesting pattern on immunofixation electrophoresis, with a complete immunoglobulin molecule, along with excess free light chains where in one light chain band shows similar mobility as the heavy chain, while the other light chain band of same isotype has a different mobility. Over a 3 year study period, 420 immunofixation electrophoresis gels were studied to select the cases with the typical pattern as described. The clinical records where searched for data of baseline evaluations done prior to starting therapy, including clinical presentation, biochemical parameters, hemogram and bone marrow examination. Twenty cases (4.7%) were identified from the records, of these 77.8% cases had renal impairment and 33.3% presented with rapidly progressive renal failure. The possible explanation is the toxic effects of excess free light chains, in our cohort. The bound LCs show mobility similar to the HC bands on serum immunofixation gels, however the free light chains, exist in polymeric forms and show a different mobility. The identification and reporting of this pattern provides additional information regarding the high load of light chains, and indicates that patient may have a poor renal outcome/performance.

Keywords

Monoclonal band Multiple myeloma Immunofixation electrophoresis Free light chains 

Notes

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical Standard

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed Consent

This was a retrospective study and for this type of study formal consent is not required.

References

  1. 1.
    Attaelmannan M, Levinson SS (2000) Understanding and identifying monoclonal gammopathies. Clin Chem 46(8 Pt 2):1230–1238PubMedGoogle Scholar
  2. 2.
    Mullikin TC, Rajkumar SV, Dispenzieri A, Buadi FK, Lacy MQ, Lin Y et al (2016) Clinical characteristics and outcomes in biclonal gammopathies. Am J Hematol 91(5):473–475CrossRefGoogle Scholar
  3. 3.
    Kyle RA, Robinson RA, Katzmann JA (1981) The clinical aspects of biclonal gammopathies. Review of 57 cases. Am J Med 71(6):999–1008CrossRefGoogle Scholar
  4. 4.
    Yang G, Geng C, Chen W (2015) Clinical characteristics of a group of patients with multiple myeloma who had two different λ light chains by immunofixation electrophoresis: a retrospective study from a single center. Exp Ther Med 9(5):1895–1900CrossRefGoogle Scholar
  5. 5.
    Misra A, Mishra J, Chandramohan J, Sharma A, Raina V, Kumar R et al (2016) Old but still relevant: high resolution electrophoresis and immunofixation in multiple myeloma. Indian J Hematol Blood Transfus 32(1):10–17CrossRefGoogle Scholar
  6. 6.
    Nair B, Waheed S, Szymonifka J, Shaughnessy JD Jr, Crowley J, Barlogie B (2009) Immunoglobulin isotypes in multiple myeloma: laboratory correlates and prognostic implications in total therapy protocols. Br J Haematol 145(1):134–137CrossRefGoogle Scholar
  7. 7.
    Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A et al (2003) Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78(1):21–33CrossRefGoogle Scholar
  8. 8.
    Cook L, Macdonald DH (2007) Management of paraproteinaemia. Postgrad Med J 83(978):217–223CrossRefGoogle Scholar
  9. 9.
    Irish AB, Winearls CG, Littlewood T (1997) Presentation and survival of patients with severe renal failure and myeloma. QJM 90(12):773–780CrossRefGoogle Scholar
  10. 10.
    Knudsen LM, Hjorth M, Hippe E (2000) Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 65(3):175–181CrossRefGoogle Scholar
  11. 11.
    Sölling K (1976) Polymeric forms of free light chains in serum from normal individuals and from patients with renal diseases. Scand J Clin Lab Invest 36(5):447–452CrossRefGoogle Scholar
  12. 12.
    Kaplan B, Livneh A, Sela BA (2011) Immunoglobulin free light chain dimers in human diseases. Sci World J 22(11):726–735CrossRefGoogle Scholar

Copyright information

© Indian Society of Hematology and Blood Transfusion 2018

Authors and Affiliations

  • Bharani Vani
    • 1
  • Aggarwal Ritu
    • 2
  • Sharma Praveen
    • 3
  • Malhotra Pankaj
    • 4
  • Ranjana Minz
    • 2
  1. 1.Department of PathologyPostgraduate Institute of Medical Education and ResearchChandigarhIndia
  2. 2.Department of ImmunopathologyPostgraduate Institute of Medical Education and ResearchChandigarhIndia
  3. 3.Department of HemotologyPostgraduate Institute of Medical Education and ResearchChandigarhIndia
  4. 4.Department of Internal MedicinePostgraduate Institute of Medical Education and ResearchChandigarhIndia

Personalised recommendations